Legal & General Group
KLRS

Legal & General Group’s Kalaris Therapeutics KLRS Stock Holding History

Legal & General Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-175
Closed -$3.04K – 3525
2024
Q1 		$3.04K Sell
175
-102
-37% -$1.66K ﹤0.01% 3331
2023
Q4 		$4.33K Sell
277
-1,300
-82% -$51.3K ﹤0.01% 3334
2023
Q3 		$78K Buy
1,577
+72
+5% +$4.91K ﹤0.01% 2842
2023
Q2 		$118K Buy
1,505
+795
+112% +$75.6K ﹤0.01% 2819
2023
Q1 		$64.3K Buy
710
+28
+4% +$3.57K ﹤0.01% 2836
2022
Q4 		$80.5K Buy
682
+50
+8% +$8.48K ﹤0.01% 2863
2022
Q3 		$114K Buy
632
+70
+12% +$10.9K ﹤0.01% 2779
2022
Q2 		$50K Buy
562
+15
+3% +$1.57K ﹤0.01% 3001
2022
Q1 		$85K Buy
547
+6
+1% +$1.2K ﹤0.01% 2905
2021
Q4 		$161K Hold
541
– – ﹤0.01% 2795
2021
Q3 		$312K Buy
541
+305
+129% +$141K ﹤0.01% 2554
2021
Q2 		$107K Buy
236
+69
+41% +$35.6K ﹤0.01% 2711
2021
Q1 		$90K Buy
167
+46
+38% +$38.7K ﹤0.01% 2648
2020
Q4 		$106K Buy
121
+33
+38% +$25.4K ﹤0.01% 2575
2020
Q3 		$55K Buy
+88
New +$60.1K ﹤0.01% 2665

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's KLRS Position: Q2 2024 in Review

Legal & General Group sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 175 shares — an estimated $3.04K sold.

Legal & General Group first reported a position in KLRS in Q3 2020 and held it in 15 quarters. The position peaked at $312K in Q3 2021. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Legal & General Group reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 175 Kalaris Therapeutics shares in Q2 2024, an estimated $3.04K.
  • Legal & General Group first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 15 quarters.
  • Legal & General Group's Kalaris Therapeutics position peaked at $312K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.